PDEX Company Profile and Key Details

Pro-Dex, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $16.90. This means the shares are trading above this model’s fair value.

Short-term trend indicators are mixed aligned (SMA20 12.09%, SMA50 10.44%, SMA200 12.63%). The stock’s 14-day RSI is 66.74 (firm momentum), while the ATR of 2.0 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -36.41% below its high and over 90.37% above its low. Average 10-day trading volume of 23.21 thousand shares is in line with the 3-month average of 25.56 thousand, indicating normal recent market interest.

Pro-Dex, Inc. generated EPS of $3.40 over the past year. Five-year average earnings growth is 12.25%. The latest quarter delivered EPS of $1.23. The next quarter is forecast at $nan. Next year's EPS is expected at $49.02. Pro-Dex, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended April 30, 2026, missed forecasts by 98.39%. The prior quarter beat by 11.86%. Over the last six quarters, Apple has recorded several small beats. These include 60.53% in January 30, 2025.

Pro-Dex, Inc. (NASDAQ:PDEX) closed at $57.42 USD, losing -$1.08 (-1.85%) from the previous close of $58.50. The stock is currently within 5% of its 52-week high $23.47 and $59.22. With a market capitalization of about $183.33 million, Pro-Dex, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.11). Key stats such as the average daily volume over the past year has been around 25.78 thousand shares, in line with its 52-week average. Headquartered in Irvine, CA, Pro-Dex, Inc. operates in the Healthcare sector and the Medical - Instruments & Supplies industry. Led by CEO Richard Lee Van Kirk Jr., the company employs approximately 146 people and listed since August 07, 1986. Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide.

Pro-Dex, Inc. has 3.26 million shares outstanding. The public float is 1.82 million shares, elevated short interest at 75.07% of float. This equals 252.81 thousand shares. The short ratio is 5.22 days. Institutional investors hold 51.37% of the float. Insiders own 35.94%. Swenson Nicholas John holds 927.18 thousand shares, CABILLOT RAYMOND E has 270.85 thousand shares and Van Kirk Richard Lee Jr has 48.91 thousand shares.

Pro-Dex, Inc. trades at a P/E ratio of 15.47, slightly below the S&P 500 average, with a price-to-sales ratio of 2.48 and a price-to-book ratio of 4.11 trading at moderately above to book value. The P/FCF stands at 26.2, also above market averages.

Pro-Dex, Inc. (NASDAQ:PDEX) shares are flat 8.45% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Pro-Dex, Inc. trading at a premium to the broader market with a P/E of 15.47. Our AI forecast model points to short-term weakness (-0.42% over two weeks), a medium-term rise (89.92% over three months), and a longer-term gain (24.7% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Pro-Dex, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.42%, with price expected at $57.18 by May 20, 2026, within a range of $55.57 to $58.71 3-Month Outlook: Projected rise of 89.92%, reaching $109.05 by August 04, 2026, with a range of $105.81 to $113.55. 1-Year Outlook: Projected gain of 24.7%, with price at $71.60 by May 06, 2027, within a range of $68.82 to $74.76.